74
Participants
Start Date
May 25, 2022
Primary Completion Date
May 22, 2025
Study Completion Date
May 3, 2027
Talquetamab
Talquetamab will be administered as a subcutaneous (SC) injection.
Teclistamab
Teclistamab will be administered as a SC injection.
PD-1 Inhibitor
The PD-1 inhibitor will be administered as an intravenous injection.
The Blavatnik Family Chelsea Medical Center at Mount Sinai, New York
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Universitaetsklinikum Hamburg Eppendorf, Hamburg
Wake Forest Baptist Medical Center, Winston-Salem
Hosp Univ Fund Jimenez Diaz, Madrid
Clinica Univ. de Navarra, Pamplona
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse
CHU de Montpellier Hopital Saint Eloi, Montpellier
Hosp Clinico Univ de Salamanca, Salamanca
Sarah Cannon Research Institute, Nashville
Vanderbilt Ingram Cancer Center, Nashville
CHU de Nantes hotel Dieu, Nantes
Universitaetsklinikum Heidelberg, Heidelberg
Colorado Blood Cancer Institute, Denver
CHU Poitiers - Hopital la Miletrie, Poitiers
Universitatsklinikum Wurzburg, Würzburg
Universitatsklinikum Carl Gustav Carus Dresden, Dresden
Hosp. Univ. Germans Trias I Pujol, Badalona
Janssen Research & Development, LLC
INDUSTRY